Current management of and future possibilities for triple negative breast cancer
Last Updated: Friday, July 17, 2026
An education session during the 2023 ASCO Annual Meeting reviewed management options and future directions for the treatment of TNBC, including immunotherapy, neoadjuvant carboplatin, and capecitabine and olaparib for high-risk disease.
Advertisement
News & Literature Highlights
